[1] Zhang XJ, Katsuta Y, Akimoto T, et al. Intrapulmonary vascular dilatation and nitric oxide in hypoxemic rats with chronic bile duct ligation. J Hepatol,2003,39:724-730.
[2] Raevens S, Fallon MB. Potential Clinical targets in hepatopulmonary syndrome: Lessons from experimental models. Hepatology,2018,68:2016-2028.
[3] Raevens S, Geerts A, Paridaens A, et al. Placental growth factor inhibition targets pulmonary angiogenesis and represents a therapy for hepatopulmonary syndrome in mice. Hepatology, 2018,68:634-651.
[4] Thenappan T, Goel A, Marsboom G, et al. A central role for CD68(+) macrophages in hepatopulmonary syndrome. Reversal by macrophage depletion. Am J Respir Crit Care Med, 2011,183:1080-1091.
[5] Sztrymf B, Rabiller A, Nunes H, et al. Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats. Eur Respir J,2004,23:752-758.
[6] Ling Y, Zhang J, Luo B, et al. The role of endothelin-1 and the endothelin B receptor in the pathogenesis of hepatopulmonary syndrome in the rat. Hepatology,2004,39:1593-1602.
[7] Yang W, Hu B, Wu W, et al. Alveolar type II epithelial cell dysfunction in rat experimental hepatopulmonary syndrome(HPS). PLoS One,2014,9:e113451.
[8] Theysohn JM, Schlaak JF, Muller S, et al. Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration. J Vasc Interv Radiol,2012,23:949-952. |
